For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by Oliver Zheng. In this video translation, Dr. Melina Marmarelis explains how mesothelioma is diagnosed and staged. Melina Marmarelis åšå£«è§£é‡Šäº†é—´çš®ç˜¤æ˜¯å¦‚何诊æ–和分期的。 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Author: Editor
For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by Oliver Zheng. In this video translation, Dr. Melina Marmarelis discusses the ways mesothelioma may be treated in the future. Melina Marmarelis åšå£«è®¨è®ºäº†æœªæ¥æ²»ç–—间皮瘤的方法。 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by Oliver Zheng. In this video translation, Dr, Chul Kim discusses Amivantamab and Mobocertinib, and their role as treatments for EGFR Exon-20 Insertion Mutations Chul Kim åšå£«è®¨è®ºäº† Amivantamab å’Œ Mobocertinib，以åŠå®ƒä»¬ä½œä¸º EGFR 外显å 20 æ’å…¥çªå˜æ²»ç–—的作用 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by Oliver Zheng. In this video translation, Dr. Ibiayi Dagogo-Jack explains the concept of “skipping” in Exon-14 NSCLC. Ibiayi Dagogo-Jack åšå£«è§£é‡Šäº† Exon-14 éžå°ç»†èƒžè‚ºç™Œä¸”跳过”的概念。 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For our Mandarin-speaking community, Oliver Zheng offers translated updates to our Lung Cancer Video Library. In this video translation, Dr. Christina Baik looks toward the future of treatments for patients with EGFR Exon-20. Christina Baik åšå£«å±•æœ› EGFR Exon-20 æ‚£è€…æ²»ç–—çš„æœªæ¥ For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
El Dr. Jared Weiss se une a nosotros para analizar la importancia de las pruebas y el diagnóstico temprano en la atención del cáncer, con énfasis en los cánceres de cabeza y cuello. En este video, el Dr. Jared Weiss analiza las formas de reducir el riesgo de cáncer de cabeza y cuello, con énfasis en la vacuna contra el VPH. Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. Gracias a nuestros patrocinadores. #Exelixis y #Merck
El Dr. Jared Weiss se une a nosotros para analizar la importancia de las pruebas y el diagnóstico temprano en la atención del cáncer, con énfasis en los cánceres de cabeza y cuello. En este video, el Dr. Jared Weiss analiza los beneficios de las pruebas regulares de detección de cáncer de cabeza y cuello. Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. Gracias a nuestros patrocinadores. #Exelixis y #Merck
El Dr. Jared Weiss se une a nosotros para analizar la importancia de las pruebas y el diagnóstico temprano en la atención del cáncer, con énfasis en los cánceres de cabeza y cuello. En este video, el Dr. Jared Weiss analiza los factores de riesgo de los cánceres de cabeza y cuello. Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. Gracias a nuestros patrocinadores. #Exelixis y #Merck
Dr. Jared Weiss joins us to discuss the importance of testing and early diagnosis in cancer care, with a concentration in head and neck cancers. In this video, Dr. Jared Weiss discusses ways to lower your risk of head and neck cancer, with emphasis on the HPV Vaccine. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Thank you to our sponsors! #Exelixis and #Merck
Dr. Jared Weiss joins us to discuss the importance of testing and early diagnosis in cancer care, with a concentration in head and neck cancers. In this video, Dr. Jared Weiss discusses the benefits of regular screening for head and neck cancers. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Thank you to our sponsors! #Exelixis and #Merck
Dr. Jared Weiss joins us to discuss the importance of testing and early diagnosis in cancer care, with a concentration in head and neck cancers. In this video, Dr. Jared Weiss discusses the risk factors for head and neck cancers. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Thank you to our sponsors! #Exelixis and #Merck
July 30, 2022 – full ONDEMAND video For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana, Medical Oncology Fellow, UCSF Helen Diller Family Comprehensive Cancer Center, Stephen Liu, Associate Professor of Medicine, Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Justin Gainor, Director, Center for Thoracic Cancers, Director of Targeted Immunotherapy, Associate Professor of Medicine at Harvard Medical School. In this series, the doctors discuss a variety of cases based on real-life scenarios. In this video Drs. Velazquez Mañana, Liu, and Gainor discuss the case…
For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana, Medical Oncology Fellow, UCSF Helen Diller Family Comprehensive Cancer Center, Stephen Liu, Associate Professor of Medicine, Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Justin Gainor, Director, Center for Thoracic Cancers, Director of Targeted Immunotherapy, Associate Professor of Medicine at Harvard Medical School. In this series, the doctors discuss a variety of cases based on real-life scenarios. In this video Drs. Velazquez Mañana, Liu, and Gainor discuss the case…
For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana, Medical Oncology Fellow, UCSF Helen Diller Family Comprehensive Cancer Center, Stephen Liu, Associate Professor of Medicine, Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Justin Gainor, Director, Center for Thoracic Cancers, Director of Targeted Immunotherapy, Associate Professor of Medicine at Harvard Medical School. In this series, the doctors discuss a variety of cases based on real-life scenarios. In this video Drs. Velazquez Mañana, Liu, and Gainor discuss the case…
For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana, Medical Oncology Fellow, UCSF Helen Diller Family Comprehensive Cancer Center, Stephen Liu, Associate Professor of Medicine, Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Justin Gainor, Director, Center for Thoracic Cancers, Director of Targeted Immunotherapy, Associate Professor of Medicine at Harvard Medical School. In this series, the doctors discuss a variety of cases based on real-life scenarios. In this video Drs. Velazquez-Manana, Liu, and Gainor discuss a 66-year-old patient…
We are excited to bring new and updated information to share through our Lung Cancer Video Library. For this video series, we are pleased to work with Dr. Christina Baik, Oncologist at Seattle Cancer Care Alliance, Associate Professor of Medicine at the University of Washington, and Associate Professor, Clinical Research Division of the Fred Hutchinson Cancer Care Research Center; Dr. Melina Marmarelis, Hematology and Oncology professional and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania; Dr. Sandip Patel, Medical Oncologist and Associate Professor of Medicine at UC San Diego Health; Dr. Tejas Patil, Medical Oncologist and…
We are excited to bring new and updated information to share through our Lung Cancer Video Library. For this video series, we are pleased to work with Dr. Christina Baik, Oncologist at Seattle Cancer Care Alliance, Associate Professor of Medicine at the University of Washington, and Associate Professor, Clinical Research Division of the Fred Hutchinson Cancer Care Research Center; Dr. Melina Marmarelis, Hematology and Oncology professional and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania; Dr. Sandip Patel, Medical Oncologist and Associate Professor of Medicine at UC San Diego Health; Dr. Tejas Patil, Medical Oncologist and…
We are excited to bring new and updated information to share through our Lung Cancer Video Library. For this video series, we are pleased to work with Dr. Christina Baik, Oncologist at Seattle Cancer Care Alliance, Associate Professor of Medicine at the University of Washington, and Associate Professor, Clinical Research Division of the Fred Hutchinson Cancer Care Research Center; Dr. Melina Marmarelis, Hematology and Oncology professional and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania; Dr. Sandip Patel, Medical Oncologist and Associate Professor of Medicine at UC San Diego Health; Dr. Tejas Patil, Medical Oncologist and…
Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present study of Adolescent and Young Adults (AYA) patients with invasive breast cancer tell us? This study was presented at the San Antonio Breast Cancer Symposium (SABCS) as a poster in 2022, and it’s a look at the effect of sociodemographic disparities on overall survival for adolescent and young adult patients with invasive breast cancer. So this is a unique population of patients within the breast cancer community. In the Adolescent and Young Adults (AYA) group, and we think about these patients age group are…
Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present study of Adolescent and Young Adults (AYA) patients with invasive breast cancer tell us? This study was presented at the San Antonio Breast Cancer Symposium (SABCS) as a poster in 2022, and it’s a look at the effect of sociodemographic disparities on overall survival for adolescent and young adult patients with invasive breast cancer. So this is a unique population of patients within the breast cancer community. In the Adolescent and Young Adults (AYA) group, and we think about these patients age group are…
iFrame is not supported! Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present study of Adolescent and Young Adults (AYA) patients with invasive breast cancer tell us? This study was presented at the San Antonio Breast Cancer Symposium (SABCS) as a poster in 2022, and it’s a look at the effect of sociodemographic disparities on overall survival for adolescent and young adult patients with invasive breast cancer. So this is a unique population of patients within the breast cancer community. In the Adolescent and Young Adults (AYA) group, and we think about…
DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan versus trastuzumab emtansine reveal for this metastatic breast cancer clinical trial? The DESTINY-Breast03 clinical trial (Daiichi Sankyo and AstraZeneca’s Trastuzumab) was a phase 3 study comparing Trastuzumab Deruxtecan to Trastuzumab Emtansine in patients treated with HER2-positive metastatic breast cancer that had previously been treated with Trastuzumab and a taxane. The first analysis of the trial results were presented in September of 2021 at ESMO where a statistically significant improvement in progression-free survival was demonstrated with the hazard ratio of 0.28 in favor of T-DXd,…
iFrame is not supported! DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan versus trastuzumab emtansine reveal for this metastatic breast cancer clinical trial? The DESTINY-Breast03 clinical trial (Daiichi Sankyo and AstraZeneca’s Trastuzumab) was a phase 3 study comparing Trastuzumab Deruxtecan to Trastuzumab Emtansine in patients treated with HER2-positive metastatic breast cancer that had previously been treated with Trastuzumab and a taxane. The first analysis of the trial results were presented in September of 2021 at ESMO where a statistically significant improvement in progression-free survival was demonstrated with the hazard ratio of…
DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan versus trastuzumab emtansine reveal for this metastatic breast cancer clinical trial? The DESTINY-Breast03 clinical trial (Daiichi Sankyo and AstraZeneca’s Trastuzumab) was a phase 3 study comparing Trastuzumab Deruxtecan to Trastuzumab Emtansine in patients treated with HER2-positive metastatic breast cancer that had previously been treated with Trastuzumab and a taxane. The first analysis of the trial results were presented in September of 2021 at ESMO where a statistically significant improvement in progression-free survival was demonstrated with the hazard ratio of 0.28 in favor of T-DXd,…
GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with newly diagnosed multiple myeloma? This is a phase 1 open label single arm study of a BCMA/CD19 Dual-Targeting CAR T cells, FasTCAR-T therapy for first line therapy for transplant eligible high newly diagnosed multiple myeloma. What is the standard of care for patients with multiple myeloma? Yes, compare with the standard of the care. Yeah, I think the very important things to understand that’s a current standard of care. Yeah, for newly diagnosed multiple myeloma patients is a 6…
iFrame is not supported! GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with newly diagnosed multiple myeloma? This is a phase 1 open label single arm study of a BCMA/CD19 Dual-Targeting CAR T cells, FasTCAR-T therapy for first line therapy for transplant eligible high newly diagnosed multiple myeloma. What is the standard of care for patients with multiple myeloma? Yes, compare with the standard of the care. Yeah, I think the very important things to understand that’s a current standard of care. Yeah, for newly diagnosed multiple myeloma…
GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with newly diagnosed multiple myeloma? This is a phase 1 open label single arm study of a BCMA/CD19 Dual-Targeting CAR T cells, FasTCAR-T therapy for first line therapy for transplant eligible high newly diagnosed multiple myeloma. What is the standard of care for patients with multiple myeloma? Yes, compare with the standard of the care. Yeah, I think the very important things to understand that’s a current standard of care. Yeah, for newly diagnosed multiple myeloma patients is a 6…
IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is IHC 0 in HER2 breast cancer patients, and how can it help? So the current study is really an expansion on previous press releases that we’ve made about the development of an algorithm that we call HER2 complete which is designed to evaluate HER2-positive and negative breast cancer cases. And we’ve really aimed it for the IHC 0 category within HER2 testing. And so what we’ve done is we were able to access an additional 900 plus cases within IHC 0 from our collaboration…
iFrame is not supported! IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is IHC 0 in HER2 breast cancer patients, and how can it help? So the current study is really an expansion on previous press releases that we’ve made about the development of an algorithm that we call HER2 complete which is designed to evaluate HER2-positive and negative breast cancer cases. And we’ve really aimed it for the IHC 0 category within HER2 testing. And so what we’ve done is we were able to access an additional 900 plus cases within IHC…
IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is IHC 0 in HER2 breast cancer patients, and how can it help? So the current study is really an expansion on previous press releases that we’ve made about the development of an algorithm that we call HER2 complete which is designed to evaluate HER2-positive and negative breast cancer cases. And we’ve really aimed it for the IHC 0 category within HER2 testing. And so what we’ve done is we were able to access an additional 900 plus cases within IHC 0 from our collaboration…
CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How will understanding patients with chronic lymphocytic leukemia (CLL) help with their treatments? First, I want to say I’m very thankful to have the opportunity to present this study on behalf of my co-investigators. We presented this as a poster presentation at ASH 2022 in New Orleans. The title is “Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments.” In the way of background, I think all clinicians know how radically the treatment paradigm in CLL (chronic lymphocytic leukemia) has shifted over…
iFrame is not supported! CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How will understanding patients with chronic lymphocytic leukemia (CLL) help with their treatments? First, I want to say I’m very thankful to have the opportunity to present this study on behalf of my co-investigators. We presented this as a poster presentation at ASH 2022 in New Orleans. The title is “Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments.” In the way of background, I think all clinicians know how radically the treatment paradigm in CLL (chronic lymphocytic…
CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How will understanding patients with chronic lymphocytic leukemia (CLL) help with their treatments? First, I want to say I’m very thankful to have the opportunity to present this study on behalf of my co-investigators. We presented this as a poster presentation at ASH 2022 in New Orleans. The title is “Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments.” In the way of background, I think all clinicians know how radically the treatment paradigm in CLL (chronic lymphocytic leukemia) has shifted over…
Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis? Navitoclax is the investigational drug, which is not currently approved. It is being studied in a condition called Myelofibrosis. It’s a bone marrow disease where there’s changes in the blood counts and patients are symptomatic, with enlarged spleen. It is being studied in a phase 2 program, and the data that are being discussed are from this ongoing phase II study. It has multiple cohorts. The data that was just presented represents a population that has not yet received the…
iFrame is not supported! Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis? Navitoclax is the investigational drug, which is not currently approved. It is being studied in a condition called Myelofibrosis. It’s a bone marrow disease where there’s changes in the blood counts and patients are symptomatic, with enlarged spleen. It is being studied in a phase 2 program, and the data that are being discussed are from this ongoing phase II study. It has multiple cohorts. The data that was just presented represents a population that has…
Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis? Navitoclax is the investigational drug, which is not currently approved. It is being studied in a condition called Myelofibrosis. It’s a bone marrow disease where there’s changes in the blood counts and patients are symptomatic, with enlarged spleen. It is being studied in a phase 2 program, and the data that are being discussed are from this ongoing phase II study. It has multiple cohorts. The data that was just presented represents a population that has not yet received the…
TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from the HPN217 (Tri-specific T Cell Activating Construct [TriTAC®]) clinical trials in TRiTAC targeting BCMA for RRMM Patients in therapeutic T-cells? Today we’re gonna talk a little bit about HBN217 (Tri-specific T Cell Activating Construct [TriTAC®]), which is a TriSpecific T-cell activating construct and relapse refractory myeloma. And this type of treatment is designed for a phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and activity of this treatment. The mechanical action of this drug, it has three domains that…
iFrame is not supported! TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from the HPN217 (Tri-specific T Cell Activating Construct [TriTAC®]) clinical trials in TRiTAC targeting BCMA for RRMM Patients in therapeutic T-cells? Today we’re gonna talk a little bit about HBN217 (Tri-specific T Cell Activating Construct [TriTAC®]), which is a TriSpecific T-cell activating construct and relapse refractory myeloma. And this type of treatment is designed for a phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and activity of this treatment. The mechanical action of this drug, it…
TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from the HPN217 (Tri-specific T Cell Activating Construct [TriTAC®]) clinical trials in TRiTAC targeting BCMA for RRMM Patients in therapeutic T-cells? Today we’re gonna talk a little bit about HBN217 (Tri-specific T Cell Activating Construct [TriTAC®]), which is a TriSpecific T-cell activating construct and relapse refractory myeloma. And this type of treatment is designed for a phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and activity of this treatment. The mechanical action of this drug, it has three domains that…
Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can Asciminib help patients with CML and were there any significant side effects? Asciminib is very much a new compound with a quite a unique mechanism of action, unlike all of the other Tyrosine kinase inhibitors (TKIs) which work by inhibiting BCR-ABL by competing with ATP, Asciminib actually binds to a distinct site in BCR-ABL, called the myristate site and switches off BCR-ABL activity by that mechanism. That provides a major advantage because you do not get the inhibition of other…
iFrame is not supported! Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can Asciminib help patients with CML and were there any significant side effects? Asciminib is very much a new compound with a quite a unique mechanism of action, unlike all of the other Tyrosine kinase inhibitors (TKIs) which work by inhibiting BCR-ABL by competing with ATP, Asciminib actually binds to a distinct site in BCR-ABL, called the myristate site and switches off BCR-ABL activity by that mechanism. That provides a major advantage because you do not get…
Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can Asciminib help patients with CML and were there any significant side effects? Asciminib is very much a new compound with a quite a unique mechanism of action, unlike all of the other Tyrosine kinase inhibitors (TKIs) which work by inhibiting BCR-ABL by competing with ATP, Asciminib actually binds to a distinct site in BCR-ABL, called the myristate site and switches off BCR-ABL activity by that mechanism. That provides a major advantage because you do not get the inhibition of other…
Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with RR large B-cell lymphoma? Today I’m going to be talking about the outreach study. So outreach study is the phase 2 prospective study evaluating the safety and efficacy of treatment with chimeric antigen receptor T-cell therapy Lisocabtagene Maraleucel (Liso-cel). Liso-cel (Liscobtagene Maraleucel) in patients with third line or later relapse or refractory large B-cell lymphoma across outpatient and inpatient setting at community or non university sites in the United States. So we know that we can give CAR T-cell…
iFrame is not supported! Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with RR large B-cell lymphoma? Today I’m going to be talking about the outreach study. So outreach study is the phase 2 prospective study evaluating the safety and efficacy of treatment with chimeric antigen receptor T-cell therapy Lisocabtagene Maraleucel (Liso-cel). Liso-cel (Liscobtagene Maraleucel) in patients with third line or later relapse or refractory large B-cell lymphoma across outpatient and inpatient setting at community or non university sites in the United States. So we know that we…
Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with RR large B-cell lymphoma? Today I’m going to be talking about the outreach study. So outreach study is the phase 2 prospective study evaluating the safety and efficacy of treatment with chimeric antigen receptor T-cell therapy Lisocabtagene Maraleucel (Liso-cel). Liso-cel (Liscobtagene Maraleucel) in patients with third line or later relapse or refractory large B-cell lymphoma across outpatient and inpatient setting at community or non university sites in the United States. So we know that we can give CAR T-cell…
RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety and fatigue in women, what were the findings? Our study was focused on determining whether there were racial or ethnic disparities in patient outcomes in the RxPONDER trial. As a reminder, the RxPONDER trial is what established the clinical utility of the 21-gene recurrence score in participants with hormone positive HER2 negative breast cancer and 1–3 positive lymph nodes. Our study objectives were to evaluate the entire cohort for clinical and pathologic characteristics by race, analyze the clinical outcomes by race, and…
iFrame is not supported! RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety and fatigue in women, what were the findings? Our study was focused on determining whether there were racial or ethnic disparities in patient outcomes in the RxPONDER trial. As a reminder, the RxPONDER trial is what established the clinical utility of the 21-gene recurrence score in participants with hormone positive HER2 negative breast cancer and 1–3 positive lymph nodes. Our study objectives were to evaluate the entire cohort for clinical and pathologic characteristics by race, analyze the clinical…
RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety and fatigue in women, what were the findings? Our study was focused on determining whether there were racial or ethnic disparities in patient outcomes in the RxPONDER trial. As a reminder, the RxPONDER trial is what established the clinical utility of the 21-gene recurrence score in participants with hormone positive HER2 negative breast cancer and 1–3 positive lymph nodes. Our study objectives were to evaluate the entire cohort for clinical and pathologic characteristics by race, analyze the clinical outcomes by race, and…
Endocrine Therapy: SABCS 2022 Halle Moore POSITIVE Trial Breast Cancer How does endocrine therapy (aromatase inhibitor) effect women with endocrine responsIVE breast cancer? The POSITIVE study which was presented at this year’s San Antonio Breast Cancer Symposium (SABCS) was a prospective clinical trial designed to evaluate the safety of and pregnancy outcomes with interrupting endocrine therapy for early stage hormone receptor positive breast cancer in order to attempt pregnancy. Young women with early stage hormone receptor positive breast cancer were eligible for the trial if they desired pregnancy and had completed 18 to 36 months of adjuvant endocrine therapy.…